In oge

Docket No.: CI-0013

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Wilson BURGESS, William N. DROHAN, Martin J. MACPHEE and David M. MANN

Serial No.:

10/024,043

Group Art Unit: 1651

Confirm. No.:

7597

Examiner: Vera Afremova

Filed:

December 21, 2001

Customer No.: 34610

For:

METHOD OF STERILIZING HEART VALVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office 2011 South Clark Place Customer Window Crystal Plaza Two, Lobby, Room 1B03 Arlington, VA 22202

Sir:

Pursuant to 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the indicated date. Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, that information cited in the statement is considered to be and/or is material to patentability, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. '120. 1138 OG 37, 38 (May 19, 1992).

Docket No. CI-0013

Serial No. 10/024,043

1. This Information Disclosure Statement is being filed (i) within three months of the U.S. filing date of a U.S. application other than a CPA continued prosecution application under '1.53(d) OR (ii) within three months of the date of entry of the national stage as set forth in '1.491 in an international application OR (iii) before the mailing date of a first Office Action on the merits. No certification or fee is required. 37 C.F.R. '1.97(b).

- X 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection OR Notice of Allowance OR an action that otherwise closes prosecution in the application. 37 C.F.R. '1.97(c).
 - X a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).
 - b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. '1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).
 - c. Attached is our check no. _____ in the amount of \$180.00 in payment of the fee under 37 C.F.R. 1.17(p). Please credit or debit Deposit Account No. 16-0607 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
 - 3. This Information Disclosure Statement is being filed after the mailing date of a Final Rejection OR Notice of Allowance OR an action that otherwise closes prosecution in the application, but on or before payment of the Issue Fee. Attached is our check no. _____ in the amount of \$180.00 in payment of the fee under 37 C.F.R. 1.17(p). Please credit or debit Deposit Account No. 16-0607 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached. 37 C.F.R. '1.97(d).
 - a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).
 - b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. '1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).
 - X 4. Others: Items (1) and (2) listed on the Search Report were previously cited in an Information Disclosure Statement filed with the U.S. Patent and Trademark Office on April 5, 2002. Therefore, copies of these documents are not enclosed herewith.

X 5. To the extent necessary, a petition for an extension of time under 37 C.F.R. 1.136 is hereby made. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 16-0607 and please credit any excess fees to such deposit account.

Respectfully submitted, FLESHNER & KIM, LLP

Donald R. McPhail Registration No. 35,811 Timothy M. Speer

P.O. Box 221200 Chantilly, Virginia 20153-1200 703 766-3701

DRM\TMS:mrh

Date: February 11, 2004

Please direct all correspondence to Customer Number 34610

APPLICANT				ATTY. DOCKET N	ATTY. DOCKET NO. CI-0013		APPLN. SERIAL NO. 10/024,043		
				APPLICANT(S) Wilson BURGESS, William N. DROHAN, Martin J. MACPHEE and David M. MANN					
FEB 1 1 2004	್ತ್ (PTO-1	CUSTOMER NO. 34610							
THE THADEWARE				FILING DATE December 21, 20	FILING DATE December 21, 2001		GROUP 1651		
U.S. PATENT	DOCUMENTS								
EXAMINER'S PATENT NO.		*ISSUE *INVEN		ENTOR NAME	NTOR NAME CLASS		SUBCLASS DATE		
	5,336,616	9/9/1994	Livesey et al.		435	240.2	2/2/1993		
		LILO DATE	NT ADDI ICA	TION PUBLICATION	ane :			1000 g (\$\frac{1}{2} \)	
	*PATENT	U.S. FAIL	NEAFFEICA	INCN: POBLICATIO	JNO TO CO		<u> </u>	76.4	
	APPLN. PUB. NO.	*PUB. DATE	*APPLICANT		CLASS	SUBCLASS			
			U.S. PATENT AI	PLICATIONS					
	*APPLN, NO.	*FILING DATE	*1	NVENTOR	CLASS	SUBCLASS			
EXAMINER'S	FOREIGN PATENT			TDOCUMENTS					
INITIALS	PATENT NO.	DATE		COUNTRY	CLASS	SUBCLASS	Transl Yes	No	
OTUED] 341 2 47	F 1 1 1 1	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Publisher, Place of Publication, Etc.)									
	A. ELDOR et. al., "Recovery of Prostacyclin Capacity of Irradiated Endothelial Cells and the Protective Effect of Vitamin C", PROSTAGLANDINS, August 1987, Vol. 34, No. 2, pp. 241-255.								
	D. JANERO et. al., "Influence of Cardioprotective Cyclooxygenase and Lipoxygenase Inhibitors								
	On Peroxidative Injury to Myocardial-Membrane Phospholipid", BIOCHEMICAL PHARMACOLOGY, Vol. 38, No. 24, pp. 4381-4387, 1989. Great Britain.								
	M. Eugène et. al., "Cryopreserved Aortic Allograft Replacement of Infected Prosthetic Grafts in								
	Man: Processing and Clinical Results", TRANSPL INT (1998) 11 (Suppl 1): S452-S454.								
EXAMINER				DATE CONSIDER	ED				